14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in Head and Neck cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Macha, Muzafar A ^a   Matta, Ajay ^b   Chauhan, S S ^a   Siu, K W Michael ^b   Ralhan, Ranju ^b,c,d  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b YORK UNIVERSITY   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYTOCHROME C; GUGGULSTERONE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN 14 3 3; PROTEIN 14 3 3 ZETA; PROTEIN BAD; PROTEIN BCL 2; PROTEIN MCL 1; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; BAD PROTEIN, HUMAN; CASPASE; CELL CYCLE PROTEIN; CELL RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; PREGNA 4,17 DIENE 3,16 DIONE; PREGNA-4,17-DIENE-3,16-DIONE; PREGNANE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HEAD AND NECK TUMOR; IMMUNOPRECIPITATION; METABOLISM; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

14-3-3 PROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPRECIPITATION; MITOCHONDRIA; PHOSPHORYLATION; PREGNENEDIONES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS;

EID: 78649483847     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-655     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer 2009. J Clin 2009, 59:225-249.
2. Bettendorf O, Piffko J, Bankfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy. Oral Oncol 2004, 40:110-119. 10.1016/j.oraloncology.2003.08.010, 14693233.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
4. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008, 371:1695-1709. 10.1016/S0140-6736(08)60728-X, 18486742.
5. Scully C, Bagan JV, Hopper C, Epstein JB. Oral cancer: current and future diagnostic techniques. Am J Dent 2008, 21:199-209.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified Squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968. 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q, 13094644.
7. Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 2009, 1:6. 10.1186/1758-3284-1-6, 2660327, 19284526.
8. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009, 6:266-277. 10.1038/nrclinonc.2009.40, 19390553.
9. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009, 115:922-935. 10.1002/cncr.24123, 19156911.
10. Shishodia S, Harikumar KB, Dass S, Ramawat KG, Aggarwal BB. The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Res 2008, 28:3647-3664.
11. Sharma B, Salunke R, Srivastava S, Majumder C, Roy P. Effects of guggulsterone isolated from Commiphora mukul in high fat diet induced diabetic rats. Food Chem Toxicol 2009, 47:2631-2639. 10.1016/j.fct.2009.07.021, 19635521.
12. Kapoor S. Guggulsterone: a potent farnesoid X receptor antagonist and its rapidly evolving role as a systemic anticarcinogenic agent. Hepatology 2008, 48:2090-2091. 10.1002/hep.22601, 18980177.
13. Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol 2007, 74:118-130. 10.1016/j.bcp.2007.03.026, 2744036, 17475222.
14. Xiao D, Singh SV. z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther 2008, 7:171-180. 10.1158/1535-7163.MCT-07-0491, 18202020.
15. Samudio I, Konopleva M, Safe S, McQueen T, Andreeff M. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 2005, 4:1982-92. 10.1158/1535-7163.MCT-05-0247, 16373713.
16. Singh SV, Zeng Y, Xiao D, Vogel VG, Nelson JB, Dhir R, Tripathi YB. Caspase-Dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 2005, 4:1747-1754. 10.1158/1535-7163.MCT-05-0223, 16275996.
17. Silva J, Dasgupta S, Wang G, Krishnamurthy K, Ritter E, Bieberich E. Lipids isolated from bone induce the migration of human breast cancer cells. J Lipid Res 2006, 47:724-33. 10.1194/jlr.M500473-JLR200, 16439808.
18. An MJ, Cheon JH, Kim SW, Kim ES, Kim TI, Kim WH. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 2009, 279:93-100. 10.1016/j.canlet.2009.01.026, 19232820.
19. Lv N, Song MY, Kim EK, Park JW, Kwon KB, Park BH. Guggulsterone, a plant sterol, inhibits NF-kappa B activation and protects pancreatic beta cells from cytokine toxicity. Mol Cell Endocrinol 2008, 289:49-59. 10.1016/j.mce.2008.02.001, 18343024.
20. Singh SV, Choi S, Zeng Y, Hahm ER, Xiao D. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 2007, 67:7439-7449. 10.1158/0008-5472.CAN-07-0120, 17671214.
21. Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 2004, 279:47148-47158. 10.1074/jbc.M408093200, 15322087.
22. Kim ES, Hong SY, Lee HK, Kim SW, An MJ, Kim TI, Lee KR, Kim WH, Cheon JH. Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. Oncol Rep 2008, 20:1321-1327.
23. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009, 30:1848-1856. 10.1093/carcin/bgp211, 2783003, 19762335.
24. Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008, 68:4406-4415. 10.1158/0008-5472.CAN-07-6696, 18519703.
25. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009, 19:16-23. 10.1016/j.tcb.2008.10.003, 19027299.
26. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008, 7:1162-1173. 10.1074/mcp.M700500-MCP200, 2424195, 18339795.
27. Ralhan R, Desouza LV, Matta A, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009, 8:300-309. 10.1021/pr800501j, 19072117.
28. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography tandem mass spectrometry. J Proteome Res 2008, 7:2078-2087. 10.1021/pr7007797, 18407684.
29. Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, Chauhan SS, Srivastava A, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Michael Siu KW. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009, 125:1398-1406. 10.1002/ijc.24517, 19548310.
30. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 2006, 16:193-202. 10.1016/j.semcancer.2006.03.003, 16697216.
31. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003, 3:931-943. 10.1038/nrc1230, 14737123.
32. Dong S, Kang S, Gu TL, Kardar S, Fu H, Lonial S, Khoury HJ, Khuri F, Chen J. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood 2007, 110:360-369. 10.1182/blood-2006-12-065615, 1896121, 17389761.
33. Zhou J, Shao Z, Kerkela R, Ichijo H, Muslin AJ, Pombo C, Force T. Serine 58 of 14-3-3 zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol Cell Biol 2009, 29:4167-4176. 10.1128/MCB.01067-08, 2715813, 19451227.
34. Lee JA, Park JE, Lee DH, Park SG, Myung PK, Park BC, Cho S. G1 to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1. Oncogene 2008, 27:1297-1305. 10.1038/sj.onc.1210740, 17700517.
35. Heyninck K, Van Huffel S, Kreike M, Beyaert R. Yeast two-hybrid screening for proteins interacting with the anti-apoptotic protein A20. Methods Mol Biol 2004, 282:223-241.
36. Matta A, DeSouza LV, Ralhan R, Siu KW. Small interfering RNA targeting 14-3-3ζ increases efficacy of chemotherapeutic agents in head and neck cancer cells. Mol Cancer Ther 2010, 9:2676-88. 10.1158/1535-7163.MCT-10-0312, 20924126.
37. Macha MA, Matta A, Sriram U, Thakkar A, Shukla NK, Datta Gupta S, Ralhan R. Clinical significance of TC21 overexpression in oral cancer. J Oral Pathol Med 2010, 39:477-85. 10.1111/j.1600-0714.2009.00854.x, 20040018.
38. Kuhar M, Sen S, Singh N. Role of mitochondria in quercetin-enhanced chemotherapeutic response in human non-small cell lung carcinoma H-520 cells. Anticancer Res 2006, 26:1297-1303.
39. Chiang CW, Kanies C, Kim KW, Fang WB, Parkhurst C, Xie M, Henry T, Yang E. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol 2003, 23:6350-6362. 10.1128/MCB.23.18.6350-6362.2003, 193703, 12944463.
40. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol 2009, 21:516-23. 10.1097/CCO.0b013e328331a7a4, 19730103.
41. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009, 61:1250-75. 10.1016/j.addr.2009.05.010, 19716393.
42. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010, 37:299-310. 10.1016/j.molcel.2010.01.025, 20159550.
43. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400:886-891. 10.1038/23730, 10476969.